Pulse Biosciences' 2027 Trial Readout Crucial to Evaluate New Pulsed Field Ablation Modality, Oppenheimer Says

MT Newswires Live10-14

Pulse Biosciences' (PLSE) strategic value is highlighted by competitors' stumbles, but much remains to be learned about the nanosecond pulsed field ablation, making the 2027 pivotal trial readout crucial to assessing the new PFA modality and nsPFA's role in the competitive landscape, Oppenheimer said Tuesday in a note.

The company's Nanopulse-AF single-arm study has completed enrollment, and while its argument of quicker and more reproducible technique remains compelling at face value, the "durability of lesion sets" will ultimately determine its success, according to the note.

While performance target for the pivotal study remains unclear, implicit

Street expectations call for patients to remain free from atrial fibrillation or atrial flutter for 12 months without antiarrhythmics, the note added.

The brokerage noted that event rate percentages with VOLT 2.0 are increasing, especially perforations and deaths. It remains unclear if there is a product design or technique issue, it added.

Oppenheimer kept an outperform rating on Pulse Biosciences and raised its price target to $60 per share from $35.

Shares of Pulse Biosciences were down 5.7% in Tuesday trading.

Price: 49.48, Change: -2.98, Percent Change: -5.67

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2675366659?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-14 00:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2675366659","market":"sh","top_or_hot":-1,"title":"Pulse Biosciences' 2027 Trial Readout Crucial to Evaluate New Pulsed Field Ablation Modality, Oppenheimer Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PLSE\">Pulse Biosciences</a>' (PLSE) strategic value is highlighted by competitors' stumbles, but much remains to be learned about the nanosecond pulsed field ablation, making the 2027 pivotal trial readout crucial to assessing the new PFA modality and nsPFA's role in the competitive landscape, Oppenheimer said Tuesday in a note.</p><p>The company's Nanopulse-AF single-arm study has completed enrollment, and while its argument of quicker and more reproducible technique remains compelling at face value, the \"durability of lesion sets\" will ultimately determine its success, according to the note.</p><p>While performance target for the pivotal study remains unclear, implicit</p><p>Street expectations call for patients to remain free from atrial fibrillation or atrial flutter for 12 months without antiarrhythmics, the note added.</p><p>The brokerage noted that event rate percentages with VOLT 2.0 are increasing, especially perforations and deaths. It remains unclear if there is a product design or technique issue, it added.</p><p>Oppenheimer kept an outperform rating on Pulse Biosciences and raised its price target to $60 per share from $35.</p><p>Shares of Pulse Biosciences were down 5.7% in Tuesday trading.</p><p>Price: 49.48, Change: -2.98, Percent Change: -5.67</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pulse Biosciences' 2027 Trial Readout Crucial to Evaluate New Pulsed Field Ablation Modality, Oppenheimer Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPulse Biosciences' 2027 Trial Readout Crucial to Evaluate New Pulsed Field Ablation Modality, Oppenheimer Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-10-14 00:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PLSE\">Pulse Biosciences</a>' (PLSE) strategic value is highlighted by competitors' stumbles, but much remains to be learned about the nanosecond pulsed field ablation, making the 2027 pivotal trial readout crucial to assessing the new PFA modality and nsPFA's role in the competitive landscape, Oppenheimer said Tuesday in a note.</p><p>The company's Nanopulse-AF single-arm study has completed enrollment, and while its argument of quicker and more reproducible technique remains compelling at face value, the \"durability of lesion sets\" will ultimately determine its success, according to the note.</p><p>While performance target for the pivotal study remains unclear, implicit</p><p>Street expectations call for patients to remain free from atrial fibrillation or atrial flutter for 12 months without antiarrhythmics, the note added.</p><p>The brokerage noted that event rate percentages with VOLT 2.0 are increasing, especially perforations and deaths. It remains unclear if there is a product design or technique issue, it added.</p><p>Oppenheimer kept an outperform rating on Pulse Biosciences and raised its price target to $60 per share from $35.</p><p>Shares of Pulse Biosciences were down 5.7% in Tuesday trading.</p><p>Price: 49.48, Change: -2.98, Percent Change: -5.67</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PLSE","symbol_name":"Pulse Biosciences, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2675366659","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2675366659","pubTimestamp":1791909612,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Pulse Biosciences'  strategic value is highlighted by competitors' stumbles, but much remains to be learned about the nanosecond pulsed field ablation, making the 2027 pivotal trial readout crucial to assessing the new PFA modality and nsPFA's role in the competitive landscape, Oppenheimer said Tuesday in a note.The company's Nanopulse-AF single-arm study has completed enrollment, and while its argument of quicker and more reproducible technique remains compelling at face value, the \"durability of lesion sets\" will ultimately determine its success, according to the note.While performance target for the pivotal study remains unclear, implicitStreet expectations call for patients to remain free from atrial fibrillation or atrial flutter for 12 months without antiarrhythmics, the note added.The brokerage noted that event rate percentages with VOLT 2.0 are increasing, especially perforations and deaths. It remains unclear if there is a product design or technique issue, it added.Oppenheime","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PLSE":"Pulse Biosciences, Inc.","BK4082":"医疗保健设备"},"translate_title":"奥本海默表示，Pulse Biosciences 2027 年试验结果对于评估新的脉冲场消融模式至关重要","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLSE":1.5},"content_text":"Pulse Biosciences' (PLSE) strategic value is highlighted by competitors' stumbles, but much remains to be learned about the nanosecond pulsed field ablation, making the 2027 pivotal trial readout crucial to assessing the new PFA modality and nsPFA's role in the competitive landscape, Oppenheimer said Tuesday in a note.The company's Nanopulse-AF single-arm study has completed enrollment, and while its argument of quicker and more reproducible technique remains compelling at face value, the \"durability of lesion sets\" will ultimately determine its success, according to the note.While performance target for the pivotal study remains unclear, implicitStreet expectations call for patients to remain free from atrial fibrillation or atrial flutter for 12 months without antiarrhythmics, the note added.The brokerage noted that event rate percentages with VOLT 2.0 are increasing, especially perforations and deaths. It remains unclear if there is a product design or technique issue, it added.Oppenheimer kept an outperform rating on Pulse Biosciences and raised its price target to $60 per share from $35.Shares of Pulse Biosciences were down 5.7% in Tuesday trading.Price: 49.48, Change: -2.98, Percent Change: -5.67","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2675366659","isCrawlerRequest":true}